View Clinical Trial (Medical Research Study)

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease - NCT01054768-94609(Clinical Trial 479234)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Oakland
State:  
CA
Zip Code: 94609
Conditions: Anemia, Sickle Cell
Purpose: The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.
Study summary: People with sickle cell disease have more inflammation (a response of body tissues to injury or irritation) than people without sickle cell disease. This inflammation can be measured in the blood by checking the level of a protein called CRP as well as other changes we see in blood due to inflammation (such as changes in platelets and other cells). There is even more inflammation during sickle-related complications (like pain or acute chest syndrome). We want to test if inflammation in people with sickle cell disease can be reduced by the use of antioxidant compounds. Antioxidants are nutrients (certain vitamins, minerals and enzymes) that can counteract the effects of oxidative stress arising from free radicals in our cells. The formation of free radicals is a normal cell process, but uncontrolled oxidative stress can cause problems for us. One such harmful problem is inflammation. We know from other research studies that antioxidants help with some conditions related to inflammation. In this study the antioxidant being tested is a combination of alpha-lipoic acid and acetyl-L-carnitine, both of which are natural parts of many of the foods we eat and are needed by our cells to make energy from food.
Criteria: Inclusion Criteria: - Proven diagnosis of sickle cell disease, either Hb SS or Hb S Beta zero thalassemia genotype - Age at entry at least 14 years. Younger children will not be included since the combination alpha-lipoic acid and acetyl-L-carnitine tablets are not available in a smaller dose at this time. Exclusion Criteria: - More than 3 packed red blood transfusions in the past 12 months - Coexisting illness that could contribute to inflammation. These include chronic hepatitis, lupus, arthritis, inflammatory bowel disease, chronic osteomyelitis, and other similar conditions. - Acute sickle cell disease related symptoms requiring a hospital visit in the past 4 weeks - Women who are pregnant, attempting to get pregnant, or breast feeding - Active participation in other investigational drug or device studies - Participants who start hydroxyurea or regular transfusion therapy during the course of the study on the recommendation of their primary hematologist will be ineligible for further participation.
Study is available at: Children's Hospital & Research Center Oakland
Oakland, CA 94609
United States

Primary Contact:
Rona Osmani
Email: rosmani@mail.cho.org
Phone: 510-428-3885

Secondary Contact:
Olivia O Vega, CCRP
Email: ovega@mail.cho.org
Phone: 510-428-3885
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.